GlassScriptPhysician profile
Olga Shvets
NPI 1689917981
$2,238.55
in general payments reported to CMS, 2019-2025
15 companies · $503 in 2025
The $503 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $95.17 · 2022: $446 · 2023: $348 · 2024: $569 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,420.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $440.29 | 2023-2025 | Nuzyra |
| Cagent Vascular INC | $329.59 | 2024-2025 | Serrantor |
| Smith+Nephew, INC. | $328.89 | 2019-2024 | Grafix Pl |
| Nevro Corp. | $213.42 | 2022-2023 | Senza |
| Treace Medical Concepts, INC. | $155.86 | 2024 | |
| Abbvie INC. | $125.00 | 2022 | |
| Wright Medical Technology, INC. | $125.00 | 2019 | |
| Advanced Oxygen Therapy INC. | $124.47 | 2024 | Topical Oxygen Chamber For Extremities |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $110.22 | 2022-2025 | Jublia, Cabtreo |
| Averitas Pharma INC. | $92.72 | 2024-2025 | Qutenza |
| Stryker Corporation | $82.46 | 2019-2023 | Asnis |
| Osteomed LLC | $45.23 | 2020 | |
| Sebela Pharmaceuticals INC. | $23.17 | 2023 | Naftin, Pramosone |
| Zimvie INC. | $21.95 | 2022 | |
| Horizon Therapeutics Plc | $20.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Shvets listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.